Elicio Therapeutics

IN THE PRESS

Press Releases

Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

January 30, 2025

·

5 min read

Press Releases

Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy

January 22, 2025

·

8 min read

Press Releases

Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024

December 12, 2024

·

9 min read

Press Releases

Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment

December 4, 2024

·

8 min read

Press Releases

Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

November 14, 2024

·

12 min read

Press Releases

Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit

October 31, 2024

·

7 min read

Press Releases

Elicio Therapeutics Reports Inducement Grants

September 17, 2024

·

2 min read

Press Releases

Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines

September 16, 2024

·

7 min read

Press Releases

Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

August 28, 2024

·

1 min read

Business

Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

August 13, 2024

·

12 min read

JOBS